Navigation Links
Idenix Pharmaceuticals to Present at an Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the Oppenheimer & Co. 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 3:20 p.m. ET at the Waldorf Astoria, New York City.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to Idenix Pharmaceuticals Contact: Jonae Barnes (617) 224-4485 (investors) Kelly Barry (617) 995-9033 (media)

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
3. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
7. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
8. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
9. Idenix Pharmaceuticals Reports First Quarter Financial Results
10. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
11. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... The ... school age children in the areas of Science, Technology, Engineering and Mathematics. The ... national economy, and the program aims to increase the number of students who ...
(Date:10/12/2015)... South Carolina (PRWEB) , ... October 12, 2015 , ... ... to announce the release of the CSM-C 600 compact clean steam generator . ... saturated steam that meets the requirements of HTM2031, HTM2010, and EN285 standards. The ...
(Date:10/12/2015)... , Oct. 12, 2015  Rebiotix Inc. today ... has designated its lead Microbiota Restoration Therapy (MRT) ... of recurrent Clostridium difficile (C diff) ... that causes 29,000 deaths in the U.S. annually. ... company that was founded to revolutionize the treatment ...
(Date:10/12/2015)... , Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris ... biopharmaceutical company engaged in developing and commercializing novel treatments ... departure of Dennis Turpin , the Company,s former ... to close its Quebec City ... President and Chief Executive Officer of the Company commented, ...
Breaking Biology Technology:
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
Breaking Biology News(10 mins):